Sunvozertinib for the treatment of NSCLC with EGFR Exon20 …
May 31, 2023 · Background: Sunvozertinib (DZD9008) is a rationally designed selective, irreversible EGFR exon20 insertion (exon20ins) inhibitor with wild-type EGFR selectivity. Here …
Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated …
Sunvozertinib (DZD9008) was designed as an oral, potent, irreversible, and selective EGFR tyrosine kinase inhibitor, showing activity against EGFR exon20ins and other mutations. In …
A multinational pivotal study of sunvozertinib in platinum …
May 29, 2024 · Background: A multinational pivotal study WU-KONG1 (NCT03974022) has been conducted to assess sunvozertinib (DZD9008) in pre-treated non-small cell lung cancer …
Sunvozertinib, a Selective EGFR Inhibitor for Previously ... - PubMed
Jul 6, 2022 · Sunvozertinib (DZD9008) was designed as an oral, potent, irreversible, and selective EGFR tyrosine kinase inhibitor, showing activity against EGFRexon20ins and other mutations. …
Preliminary safety and efficacy results from phase 1 studies of DZD9008 …
May 28, 2021 · DZD9008 is a rationally designed selective, irreversible EGFR exon20ins inhibitor being studied in two ongoing phase 1/2 studies (NCT03974022 and CTR20192097). Methods: …
FDA Grants Breakthrough Therapy Designation to First-Line
Apr 8, 2024 · The FDA has granted breakthrough therapy designation to sunvozertinib (DZD9008) as frontline treatment for patients with locally advanced or metastatic non–small cell lung …
FDA Grants Breakthrough Therapy Designation to DZD9008 for …
Jan 27, 2022 · DZD9008 is a selective, irreversible EGFR inhibitor, which is currently being evaluated for the treatment of both EGFR exon20 insertion mutation-positive NSCLC and …
OA15.02 Phase 1 Studies of DZD9008, an Oral Selective …
Oct 1, 2021 · DZD9008 showed a favourable safety profile and promising anti-tumor efficacy in pre-treated NSCLC with EGFR exon20ins and other EGFR or HER2 mutations. DZD9008 is …
Abstract 3081: DZD9008, an oral, wild type selective EGFR …
Jul 1, 2019 · DZD9008 is an oral, potent, irreversible, wild type-selective EGFR TKI against EGFR or HER2 Exon20ins and other mutations. The present study shows anti-tumor activity of …
OA15.02 Phase 1 Studies of DZD9008, an Oral Selective …
DZD9008 showed a favourable safety profile and promising anti-tumor efficacy in pre-treated NSCLC with EGFR exon20ins and other EGFR or HER2 mutations. DZD9008 is currently in …